These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 3674795)
1. Effects of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795 [TBL] [Abstract][Full Text] [Related]
2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jenike MA; Albert MS; Heller H; Gunther J; Goff D J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997 [TBL] [Abstract][Full Text] [Related]
3. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush S; Guterman A; Villalon AV J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560 [TBL] [Abstract][Full Text] [Related]
4. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605 [TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Canal N; Imbimbo BP Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240 [TBL] [Abstract][Full Text] [Related]
6. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Wettstein A Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183 [TBL] [Abstract][Full Text] [Related]
7. Long-term administration of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658 [TBL] [Abstract][Full Text] [Related]
18. Cortisol responses to cholinergic drugs in Alzheimer's disease. Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Antuono PG Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110 [TBL] [Abstract][Full Text] [Related]
20. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]